These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34189655)

  • 1. FDA's Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes.
    Wang Y; Qin B; Xia G; Choi SH
    AAPS J; 2021 Jun; 23(4):92. PubMed ID: 34189655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current trends in PLGA based long-acting injectable products: The industry perspective.
    Muddineti OS; Omri A
    Expert Opin Drug Deliv; 2022 May; 19(5):559-576. PubMed ID: 35534912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation.
    Park K; Skidmore S; Hadar J; Garner J; Park H; Otte A; Soh BK; Yoon G; Yu D; Yun Y; Lee BK; Jiang X; Wang Y
    J Control Release; 2019 Jun; 304():125-134. PubMed ID: 31071374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reverse Engineering the 1-Month Lupron Depot®.
    Zhou J; Hirota K; Ackermann R; Walker J; Wang Y; Choi S; Schwendeman A; Schwendeman SP
    AAPS J; 2018 Oct; 20(6):105. PubMed ID: 30280294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical-Chemical Characterization of Octreotide Encapsulated in Commercial Glucose-Star PLGA Microspheres.
    Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Qin B; Schwendeman SP
    Mol Pharm; 2020 Nov; 17(11):4141-4151. PubMed ID: 32876463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
    Somayaji MR; Das D; Przekwas A
    Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex sameness: Separation of mixed poly(lactide-co-glycolide)s based on the lactide:glycolide ratio.
    Skidmore S; Hadar J; Garner J; Park H; Park K; Wang Y; Jiang XJ
    J Control Release; 2019 Apr; 300():174-184. PubMed ID: 30853529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of polymer source on in vitro drug release from PLGA microspheres.
    Wan B; Andhariya JV; Bao Q; Wang Y; Zou Y; Burgess DJ
    Int J Pharm; 2021 Sep; 607():120907. PubMed ID: 34332059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of PLGA molecular weight differences on risperidone release from microspheres.
    Kohno M; Andhariya JV; Wan B; Bao Q; Rothstein S; Hezel M; Wang Y; Burgess DJ
    Int J Pharm; 2020 May; 582():119339. PubMed ID: 32305366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Complications of Poly(lactic-
    Lim YW; Tan WS; Ho KL; Mariatulqabtiah AR; Abu Kasim NH; Abd Rahman N; Wong TW; Chee CF
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
    Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.
    Li T; Chandrashekar A; Beig A; Walker J; Hong JKY; Benet A; Kang J; Ackermann R; Wang Y; Qin B; Schwendeman AS; Schwendeman SP
    Eur J Pharm Biopharm; 2021 Jan; 158():401-409. PubMed ID: 33122118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and etoposide-loaded Poly (lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for dual drug delivery.
    Zhang M; Tang Y; Zhu Z; Zhao H; Yao J; Sun D
    J Biomater Sci Polym Ed; 2018 Nov; 29(16):1949-1963. PubMed ID: 29920151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution testing for generic drugs: an FDA perspective.
    Anand O; Yu LX; Conner DP; Davit BM
    AAPS J; 2011 Sep; 13(3):328-35. PubMed ID: 21479700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles.
    Park K; Otte A; Sharifi F; Garner J; Skidmore S; Park H; Jhon YK; Qin B; Wang Y
    J Control Release; 2021 Jan; 329():1150-1161. PubMed ID: 33148404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review.
    Hua Y; Su Y; Zhang H; Liu N; Wang Z; Gao X; Gao J; Zheng A
    Drug Deliv; 2021 Dec; 28(1):1342-1355. PubMed ID: 34180769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Roles of the Glass Transition Temperature of PLGA Microparticles in Drug Release Kinetics.
    Park K; Otte A; Sharifi F; Garner J; Skidmore S; Park H; Jhon YK; Qin B; Wang Y
    Mol Pharm; 2021 Jan; 18(1):18-32. PubMed ID: 33331774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the drug encapsulation of poly(lactic-
    Dodda JM; Remiš T; Rotimi S; Yeh YC
    J Mater Chem B; 2022 Jun; 10(22):4127-4141. PubMed ID: 35593381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
    Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
    AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.